-
Je něco špatně v tomto záznamu ?
Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications
F. Angelucci, K. Čechová, R. Průša, J. Hort,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2019
PubMed Central
od 2008
Europe PubMed Central
od 2008 do 2020
ProQuest Central
od 2019-01-01
Medline Complete (EBSCOhost)
od 2008-03-01
Health & Medicine (ProQuest)
od 2019-01-01
Wiley-Blackwell Open Access Titles
od 2008
ROAD: Directory of Open Access Scholarly Resources
od 2008
PubMed
30403004
DOI
10.1111/cns.13082
Knihovny.cz E-zdroje
- MeSH
- Alzheimerova nemoc diagnóza farmakoterapie metabolismus MeSH
- amyloidní beta-protein metabolismus MeSH
- extracelulární prostor účinky léků metabolismus MeSH
- lidé MeSH
- mozkový neurotrofický faktor metabolismus MeSH
- plazminogen metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Soluble oligomeric forms of amyloid beta (Aβ) play an important role in causing the cognitive deficits in Alzheimer's disease (AD) by targeting and disrupting synaptic pathways. Thus, the present research is directed toward identifying the neuronal pathways targeted by soluble forms and, accordingly, develops alternative therapeutic strategies. The neurotrophin brain-derived neurotrophic factor (BDNF) is synthesized as a precursor (pro-BDNF) which is cleaved extracellularly by plasmin to release the mature form. The conversion from pro-BDNF to BDNF is an important process that regulates neuronal activity and memory processes. Plasmin-dependent maturation of BDNF in the brain is regulated by plasminogen activator inhibitor-1 (PAI-1), the natural inhibitor of tissue-type plasminogen activator (tPA). Therefore, tPA/PAI-1 system represents an important regulator of extracellular BDNF/pro-BDNF ratio. In this review, we summarize the data on the components of the plasminogen activation system and on BDNF in AD. Moreover, we will hypothesize a possible pathogenic mechanism caused by soluble Aβ forms based on the effects on tPA/PAI-1 system and on the consequence of an altered conversion from pro-BDNF to the mature BDNF in the brain of AD patients. Translation into clinic may include a better characterization of the disease stage and future direction on therapeutic targets.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20022854
- 003
- CZ-PrNML
- 005
- 20201214124858.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/cns.13082 $2 doi
- 035 __
- $a (PubMed)30403004
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Angelucci, Francesco $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
- 245 10
- $a Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications / $c F. Angelucci, K. Čechová, R. Průša, J. Hort,
- 520 9_
- $a Soluble oligomeric forms of amyloid beta (Aβ) play an important role in causing the cognitive deficits in Alzheimer's disease (AD) by targeting and disrupting synaptic pathways. Thus, the present research is directed toward identifying the neuronal pathways targeted by soluble forms and, accordingly, develops alternative therapeutic strategies. The neurotrophin brain-derived neurotrophic factor (BDNF) is synthesized as a precursor (pro-BDNF) which is cleaved extracellularly by plasmin to release the mature form. The conversion from pro-BDNF to BDNF is an important process that regulates neuronal activity and memory processes. Plasmin-dependent maturation of BDNF in the brain is regulated by plasminogen activator inhibitor-1 (PAI-1), the natural inhibitor of tissue-type plasminogen activator (tPA). Therefore, tPA/PAI-1 system represents an important regulator of extracellular BDNF/pro-BDNF ratio. In this review, we summarize the data on the components of the plasminogen activation system and on BDNF in AD. Moreover, we will hypothesize a possible pathogenic mechanism caused by soluble Aβ forms based on the effects on tPA/PAI-1 system and on the consequence of an altered conversion from pro-BDNF to the mature BDNF in the brain of AD patients. Translation into clinic may include a better characterization of the disease stage and future direction on therapeutic targets.
- 650 _2
- $a Alzheimerova nemoc $x diagnóza $x farmakoterapie $x metabolismus $7 D000544
- 650 _2
- $a amyloidní beta-protein $x metabolismus $7 D016229
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mozkový neurotrofický faktor $x metabolismus $7 D019208
- 650 _2
- $a extracelulární prostor $x účinky léků $x metabolismus $7 D005110
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plazminogen $x metabolismus $7 D010958
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Čechová, Kateřina $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic.
- 700 1_
- $a Průša, Richard $u Department of Medical Chemistry and Clinical Biochemistry, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
- 700 1_
- $a Hort, Jakub $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic.
- 773 0_
- $w MED00173405 $t CNS neuroscience & therapeutics $x 1755-5949 $g Roč. 25, č. 3 (2019), s. 303-313
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30403004 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214124858 $b ABA008
- 999 __
- $a ok $b bmc $g 1595173 $s 1113530
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 25 $c 3 $d 303-313 $e 20181106 $i 1755-5949 $m CNS neuroscience & therapeutics $n CNS Neurosci Ther $x MED00173405
- LZP __
- $a Pubmed-20201125